USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
HOUSEY PHARMACEUTICAL RESEARCH LAB
Address:
16800 W 12 MILE RD, STE 201
SOUTHFIELD, MI
Phone:
N/A
URL:
N/A
EIN:
383627198
DUNS:
611659819
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $249,616.00 2
SBIR Phase II $3,757,480.00 2

Award List:

Discovery and development of Antidiabetic Drugs

Award Year / Program / Phase:
2003 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): This Phase I SBIR application entitled "Discovery and Development of Antidiabetic Drugs," proposes to establish assay systems to identify and validate small molecules that promote the function of the insulin receptor substrate 2 (IRS2) in mammalian cells. IRS2… More

Discovery and Development of Anti-Diabetic Drugs.

Award Year / Program / Phase:
2006 / SBIR / Phase II
Award Amount:
$852,467.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): This is the Phase 2 application entitled "Discovery and Development of Antidiabetic Drugs." The goal is to identify new molecular entities that promote the IRS2-branch of the insulin/IGF signaling system. The NIH support will be used to identify compounds that… More

Novel Inhibitors for the Treatment of Highly Drug-Resistant Chronic Myelogenous

Award Year / Program / Phase:
2009 / SBIR / Phase I
Award Amount:
$149,616.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): This is the Phase 1 application of an SBIR proposal entitled Novel Inhibitors for the Treatment of Highly Drug Resistant Chronic Myelogenous Leukemia. The overall goal of this proposal is to test the efficacy of a cla ss of novel small molecule scaffolds, which… More

Discovery and Development of Anti-Diabetic Drugs.

Award Year / Program / Phase:
2011 / SBIR / Phase II
Award Amount:
$2,905,013.00
Agency:
HHS
Principal Investigator:
Gerard M. Housey – 248-663-7000
Abstract:
DESCRIPTION (provided by applicant): This is a Resubmission of an NIH Phase II SBIR Renewal Application directed towards developing and optimizing compounds that are capable of stimulating IRS2 foundation for the treatment of Type II diabetes. If successful, such compounds may also be useful for the… More